Hoth Therapeutics, Inc., a clinical-stage biopharma company, has engaged ICON Clinical Research Ltd. to expand its Phase II clinical trial for cancer patients with skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi). Additional regulatory approval for the Phase II trial is expected from potentially three EU countries in the upcoming months. The EU approval is part of the company’s international clinical development strategy for HT-001. The trial is curren...